Lyra Therapeutics Inc. (LYRA): Price and Financial Metrics

Lyra Therapeutics Inc. (LYRA): $8.99

0.20 (+2.28%)

POWR Rating

Component Grades













LYRA Stock Price Chart Interactive Chart >

Price chart for LYRA

LYRA Price/Volume Stats

Current price $8.99 52-week high $16.50
Prev. close $8.79 52-week low $5.83
Day low $8.76 Volume 23,560
Day high $9.18 Avg. volume 113,776
50-day MA $7.34 Dividend yield N/A
200-day MA $9.74 Market Cap 116.88M

Lyra Therapeutics Inc. (LYRA) Company Bio

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer and is headquartered in Watertown, MA.

LYRA Latest News Stream

Event/Time News Detail
Loading, please wait...

LYRA Latest Social Stream

Loading social stream, please wait...

View Full LYRA Social Stream

Latest LYRA News From Around the Web

Below are the latest news stories about Lyra Therapeutics Inc that investors may wish to consider to help them evaluate LYRA as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investors!

William White on InvestorPlace | June 9, 2021

Lyra Therapeutics: Advancements In Clinical Development Pipeline Could Send Shares Soaring

Based in Watertown, Massachusetts, Lyra Therapeutics, Inc. (LYRA) is a clinical stage biotechnology company, which develops a proprietary technology platform. The platform provides a treatment alternative to patients seeking care for ear, nose and throat diseases for which conventional medical approaches are either a second treatment option or have already failed to produce needed results. Lyra’s therapies are based on a single administration of anti-inflammatory bioresorbable polymer implants that are applied directly on the inflamed mucosa. These implants act continually for a sustained period of several months.   The research and development pipeline includes LYR-210 and LYR-220, two innovative therapeutic solutions for the treatment of chronic rhinosinusitis.

TipRanks Team on TipRanks | April 27, 2021

Read More 'LYRA' Stories Here

LYRA Price Returns

1-mo 26.26%
3-mo 4.29%
6-mo -24.45%
1-year -21.42%
3-year N/A
5-year N/A
YTD -21.14%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 4.1381 seconds.